What is really known about the effects of nicotinamide riboside supplementation in humans

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

What is really known about the effects of nicotinamide riboside supplementation in humans. / Damgaard, Mads V.; Treebak, Jonas T.

In: Science Advances, Vol. 9, No. 29, eadi4862, 2023.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Damgaard, MV & Treebak, JT 2023, 'What is really known about the effects of nicotinamide riboside supplementation in humans', Science Advances, vol. 9, no. 29, eadi4862. https://doi.org/10.1126/sciadv.adi4862

APA

Damgaard, M. V., & Treebak, J. T. (2023). What is really known about the effects of nicotinamide riboside supplementation in humans. Science Advances, 9(29), [eadi4862]. https://doi.org/10.1126/sciadv.adi4862

Vancouver

Damgaard MV, Treebak JT. What is really known about the effects of nicotinamide riboside supplementation in humans. Science Advances. 2023;9(29). eadi4862. https://doi.org/10.1126/sciadv.adi4862

Author

Damgaard, Mads V. ; Treebak, Jonas T. / What is really known about the effects of nicotinamide riboside supplementation in humans. In: Science Advances. 2023 ; Vol. 9, No. 29.

Bibtex

@article{c36b1c329d134d4ca4d4484b64308f6a,
title = "What is really known about the effects of nicotinamide riboside supplementation in humans",
abstract = "Nicotinamide riboside is a precursor to the important cofactor nicotinamide adenine dinucleotide and has elicitedmetabolic benefits in multiple preclinical studies. In 2016, the first clinical trial of nicotinamide ribosidewasconducted to test the safety and efficacy of human supplementation. Many trials have since been conductedaiming to delineate benefits to metabolic health and severe diseases in humans. This review endeavors to summarizeand critically assess the 25 currently published research articles on human nicotinamide riboside supplementationto identify any poorly founded claims and assist the field in elucidating the actual future potentialfor nicotinamide riboside. Collectively, oral nicotinamide riboside supplementation has displayed few clinicallyrelevant effects, and there is an unfortunate tendency in the literature to exaggerate the importance and robustnessof reported effects. Even so, nicotinamide riboside may play a role in the reduction of inflammatorystates and has shown some potential in the treatment of diverse severe diseases.",
author = "Damgaard, {Mads V.} and Treebak, {Jonas T.}",
year = "2023",
doi = "10.1126/sciadv.adi4862",
language = "English",
volume = "9",
journal = "Science advances",
issn = "2375-2548",
publisher = "American Association for the Advancement of Science",
number = "29",

}

RIS

TY - JOUR

T1 - What is really known about the effects of nicotinamide riboside supplementation in humans

AU - Damgaard, Mads V.

AU - Treebak, Jonas T.

PY - 2023

Y1 - 2023

N2 - Nicotinamide riboside is a precursor to the important cofactor nicotinamide adenine dinucleotide and has elicitedmetabolic benefits in multiple preclinical studies. In 2016, the first clinical trial of nicotinamide ribosidewasconducted to test the safety and efficacy of human supplementation. Many trials have since been conductedaiming to delineate benefits to metabolic health and severe diseases in humans. This review endeavors to summarizeand critically assess the 25 currently published research articles on human nicotinamide riboside supplementationto identify any poorly founded claims and assist the field in elucidating the actual future potentialfor nicotinamide riboside. Collectively, oral nicotinamide riboside supplementation has displayed few clinicallyrelevant effects, and there is an unfortunate tendency in the literature to exaggerate the importance and robustnessof reported effects. Even so, nicotinamide riboside may play a role in the reduction of inflammatorystates and has shown some potential in the treatment of diverse severe diseases.

AB - Nicotinamide riboside is a precursor to the important cofactor nicotinamide adenine dinucleotide and has elicitedmetabolic benefits in multiple preclinical studies. In 2016, the first clinical trial of nicotinamide ribosidewasconducted to test the safety and efficacy of human supplementation. Many trials have since been conductedaiming to delineate benefits to metabolic health and severe diseases in humans. This review endeavors to summarizeand critically assess the 25 currently published research articles on human nicotinamide riboside supplementationto identify any poorly founded claims and assist the field in elucidating the actual future potentialfor nicotinamide riboside. Collectively, oral nicotinamide riboside supplementation has displayed few clinicallyrelevant effects, and there is an unfortunate tendency in the literature to exaggerate the importance and robustnessof reported effects. Even so, nicotinamide riboside may play a role in the reduction of inflammatorystates and has shown some potential in the treatment of diverse severe diseases.

U2 - 10.1126/sciadv.adi4862

DO - 10.1126/sciadv.adi4862

M3 - Journal article

C2 - 37478182

VL - 9

JO - Science advances

JF - Science advances

SN - 2375-2548

IS - 29

M1 - eadi4862

ER -

ID: 361377698